[The prospects for using the new macrolide antibiotic azithromycin (Sumamed) in the combined treatment of periodontitis].
Antibacterial activity of sumamed, a macrolide antibiotic, in respect of anaerobic microflora of the oral cavity, such as Bacteroides, Prevotella, Porphyromonas, Fusobacterium, Peptostreptococcus, Str. sanguis and Staph. aureus, was assessed. The drug was found to be highly effective in respect of bacteroids (MPC90: 1,4 to 30 mg/mlMg/ml, this permitting the use of sumamed in the treatment of 9 patients with chronic generalized periodontitis in the exacerbation stage. Bacteriological and clinical control of the results of therapy demonstrated the drug efficacy in respect of periodontopathogenous flora, particularly as regards bacteroids and fusobacteria which maintain the inflammatory process in periodontitis.